5-HT2B Receptor Antagonists Inhibit Fibrosis and Protect from RV Heart Failure

Figure 2

Effects of 5-HT2BR blockade on hemodynamics and cardiac performance. Hemodynamic catheter measurements of pulmonary artery banding (PAB) challenged mice showed no change in systolic (a) and diastolic (b) systemic blood pressure. Treatment with Terguride (0.2 mg/kg bodyweight) or SB204741 (5 mg/kg bodyweight) did not affect systemic parameters. Heart rate (HR) was not affected by PAB-operation or serotonin receptor blockade (c). Chronic constriction of the pulmonary artery decreased cardiac output compared to sham-operated controls significantly (d). Magnetic resonance imaging revealed significant cardiac performance improvement due to the administration of Terguride or SB204741 compared to placebo-treated animals. Data are presented as mean ± SEM. animals in catheterized untreated control groups and animals in all treated and MRI groups, respectively. versus placebo-treated control.

(a)

(b)

(c)

(d)